Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetRevenue - OtherRevenue - Rental
Ratios

Maxcyte (MXCT) Leases (2020 - 2025)

Maxcyte (MXCT) has disclosed Leases for 6 consecutive years, with $11.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Leases rose 2.27% to $11.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.1 million, a 2.27% increase, with the full-year FY2024 number at $10.8 million, down 4.23% from a year prior.
  • Leases was $11.1 million for Q3 2025 at Maxcyte, down from $11.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $11.5 million in Q1 2025 to a low of $170700.0 in Q2 2021.
  • A 5-year average of $9.2 million and a median of $10.6 million in 2022 define the central range for Leases.
  • Peak YoY movement for Leases: soared 6010.31% in 2022, then decreased 10.5% in 2023.
  • Maxcyte's Leases stood at $5.7 million in 2021, then surged by 73.18% to $9.9 million in 2022, then increased by 14.09% to $11.2 million in 2023, then fell by 4.23% to $10.8 million in 2024, then rose by 3.43% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Leases are $11.1 million (Q3 2025), $11.3 million (Q2 2025), and $11.5 million (Q1 2025).